Navigation Links
A Phase II, Randomized, Double Blind, Placebo-Controlled Dose-Escalating Study, Meets the Clinical Endpoints of MTR106 Tablets During the Treatment of Acute Migraine Attacks Without Aura in Females
Date:11/6/2007

REHOVOT, Israel, Nov. 6 /PRNewswire/ -- Meditor Pharmaceuticals Ltd. announced today that the primary end point and safety evaluation in the Phase II, Randomized Double Blind, Placebo-Controlled Dose-Escalating Study in Migraine patients was successfully completed. This event marks a major milestone in the development program of the compound MTR106 (tablet formulation of MTR104). MTR104 is a low molecular weight S-Alkylisothiouronium derivative.

This Phase II study was designed to assess the pharmacokinetics, safety and efficacy of MTR106 in female patients suffering from migraine without aura. The study population consisted of forty (40) female patients ranging from 22-57 years of age. The average duration of migraine attacks was 16.6 +/- 10 hours with a frequency of 2.8 +/- 1.3 attacks per month. The subjects were randomized in a ratio of 4:1: treatment to placebo respectively, constituting 4 groups of 10 patients each. Treatment arms of MTR106 or placebo were administered at escalating doses of 25, 50, 75 and 100 mg.

MTR106 was found to be safe and well tolerated. No serious adverse events occurred in the 4 studied doses and no symptoms related to chest pain or changes in heart rate or blood pressure were observed. The study results demonstrated that at 2 hours and at the 3rd and 4th hours post-treatment more patients treated with MTR106 had pain relief compared to those treated with placebo.

About Meditor Pharmaceuticals:

Meditor Pharmaceuticals Ltd. is a biopharmaceutical company dedicated to the development and commercialization of proprietary products for the therapeutic management of acute and chronic hypotension and hypotension-related disorders. The lead development compound is a low molecular weight S-Alkylisothiouronium derivative that addresses a variety of acute and chronic therapeutic indications associated with hypotension. The clinical development program is focused on the development of lead compound MTR104 for the tr
'/>"/>

SOURCE Meditor Pharmaceuticals Ltd.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
3. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
4. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
7. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
8. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
9. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
10. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
11. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/15/2008)...Antiplatelet Therapy that, Combined, with Aspirin,...ix/Iscover and Aspirin, According to a New Rep...15 /- Decision Resources, one of the,...armaceutical and,healthcare issues, finds that Dai... in patient compared to Sanofi-Aventis/Bristol Mye...
(Date:5/15/2008)...ares Genous, Boston Scientific,s ...on Real-World Use of Genous, Stent,s Performance ... Dual-Antiplatelet ... OrbusNeich today announced,that multiple clinical...,support the use of the company,s Genous Bio-engin...
(Date:5/14/2008)...ire-FirstCall/ -- Progen,Pharmaceuticals Limited (...mpany has resumed patient enrolment in the phase 1...lyamine analogue, PG-11047 (formerly CGC-11047),fo...enced development of PG-11047 - the lead clinical,...owing its acquisition of,Cellgate, Inc earlier thi...
(Date:5/14/2008)... for cervical cancer prevention, GRAZ, Austria, M...xtended follow-up study show that GlaxoSmithKline ...ERVARIX(R) generates sustained high levels of,neut...rvical cancer-causing,human papillomavirus types f...f sustained neutralizing antibody levels observed ...
Breaking Medicine Technology:Daiichi Sankyo/Eli Lilly's Effient and Astrazeneca's Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction 2Daiichi Sankyo/Eli Lilly's Effient and Astrazeneca's Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction 3Multiple Clinical Data Presentations at EuroPCR 2008 Support Use of OrbusNeich's Genous(TM) Bio-engineered R stent(TM) as Safe Alternative to Drug-Eluting Stents 2Multiple Clinical Data Presentations at EuroPCR 2008 Support Use of OrbusNeich's Genous(TM) Bio-engineered R stent(TM) as Safe Alternative to Drug-Eluting Stents 3Multiple Clinical Data Presentations at EuroPCR 2008 Support Use of OrbusNeich's Genous(TM) Bio-engineered R stent(TM) as Safe Alternative to Drug-Eluting Stents 4Progen Resumes Phase 1 Development of Anti-Cancer Agent, PG-11047 2CERVARIX(R) Shown to Provide Longest Duration of Sustained Neutralizing Antibodies to Date 2CERVARIX(R) Shown to Provide Longest Duration of Sustained Neutralizing Antibodies to Date 3CERVARIX(R) Shown to Provide Longest Duration of Sustained Neutralizing Antibodies to Date 4CERVARIX(R) Shown to Provide Longest Duration of Sustained Neutralizing Antibodies to Date 5CERVARIX(R) Shown to Provide Longest Duration of Sustained Neutralizing Antibodies to Date 6EaglePicher Medical Power Names Joseph Marotta Vice President of Sales and Marketing 14008 1EaglePicher Medical Power Names Joseph Marotta Vice President of Sales and Marketing 14008 2Colon Cancer Screening Laws Now Cover Half of U S Population 3861 1Colon Cancer Screening Laws Now Cover Half of U S Population 3861 2Colon Cancer Screening Laws Now Cover Half of U S Population 3861 3Colon Cancer Screening Laws Now Cover Half of U S Population 3861 4Colon Cancer Screening Laws Now Cover Half of U S Population 3861 5DURECT to Participate in Cowen Annual Healthcare Conference 14005 1Outcomes Improve for Non Hodgkin Lymphoma Patients 14002 1Outcomes Improve for Non Hodgkin Lymphoma Patients 14002 2
...LIS, France, May 11, 2007 /PRNewswire-FirstCall/ -...ate on the phase 2a,study for NCX 1000, which is c...harma Inc. A preliminary analysis of 11 patients,...nsion confirmed,the safety profile of NCX 1000 but...ort the continuation of this clinical trial. As a,...
...(BUSINESS WIRE)--May 14, 2007 - Acceleron Pharma,...peutics for the,treatment of musculoskeletal, meta... results of a preclinical study with,ACE-031 that ...se,muscle mass and strength in normal mice and in ...its negative regulators of muscle,to increase musc...
Other Medicine Technology:NicOx Provides an Update on the Phase 2a Study for NCX 1000,Conducted With Axcan 2NicOx Provides an Update on the Phase 2a Study for NCX 1000,Conducted With Axcan 3Acceleron Pharma's ACE-031 Increases Muscle Mass and Strength in,Preclinical Studies 2Acceleron Pharma's ACE-031 Increases Muscle Mass and Strength in,Preclinical Studies 3
(Date:5/16/2008)...rstCall/ -- Tempo Participacoes,S.A. (Bovespa: TEM...ding,provider of healthcare administration service... services, announces today its results for the fir...formation contained herein,except where otherwise...,accordance with Brazilian Stock Exchange Commissi...
(Date:5/15/2008)...sing in Targeting Cancer Cells, ...ay 15 /PRNewswire-FirstCall/ -- Abbott scientists,...everal investigative,compounds in the company,s on... Clinical Oncology (ASCO) Annual Meeting, schedule... ABT-263, a Bcl-2 family protein,antagonist, and A...
(Date:5/15/2008)...ng cancer treatment for each individual, researche...resented a study suggesting a simple blood test ca...cacy for patients with metastatic breast cancer. ,...to determine if a particular cancer treatment is w...y significant radiographic changes in tumor size o...
(Date:5/15/2008)...tCall/ -- Digital Power,Corporation (Amex: DPW ) ...cial results for the first quarter ended March 31,...000 for the quarter ended,March 31, 2008, an incre...last year. An operating loss of $165,000 for the f...operating profit of $25,000 for the same quarter,l...
Breaking Medicine News(10 mins):Health News:Abbott to Present Data on Novel Cancer Treatments at American Society of Clinical Oncology Annual Meeting 2Health News:Abbott to Present Data on Novel Cancer Treatments at American Society of Clinical Oncology Annual Meeting 3Health News:Abbott to Present Data on Novel Cancer Treatments at American Society of Clinical Oncology Annual Meeting 4Health News:Abbott to Present Data on Novel Cancer Treatments at American Society of Clinical Oncology Annual Meeting 5Health News:Abbott to Present Data on Novel Cancer Treatments at American Society of Clinical Oncology Annual Meeting 6Health News:Study suggests blood test can help improve treatment outcomes for breast cancer patients 2Health News:Digital Power Reports Financial Results for the First Quarter Ended March 31, 2008 2Health News:Digital Power Reports Financial Results for the First Quarter Ended March 31, 2008 3
... North America with an estimated 400,000 people fa...of these //people have their hearts pumping again ...of the main causes of death after the heart is res...esented at the 2006 Society for Academic Emergency...
...cos here have collapsed due to fasting in the past...fight against// reservation for backward classes w...ecision. "Ninety-four doctors have so far collapse...e hunger strike. Currently 35 of them are still si...
...people to get themselves screened for HIV, city-ru...criteria// for HIV testing. According to the new r...ent is not neccessary for voluntary HIV/AIDS testi...consent from the patient. This rule makes it the ...
...e discovered the cause for people to overeat. Scie...it's in the brain//. Researchers at the council's... the first neurobiological proof as to why some pe...research, published today in the Journal of Neuros...
Other Medicine News:Health News:Survival After Cardiac Arrest Is Aided By Cooling 2Health News:Despite Collapse Of The Medicos Strike To Continue Unabated 2Health News:Research Scans Explain Why People Crave For Food 2
...: The HF-compatible V series from Pentax, the stan...asured., ,The HF-compatible series of fibre bronc...V and FB-15V models along with the very slim FB-10... quality thanks mainly to the higher resolution an...
...m the latest 60 series bronchoscopes., ,Olymp... providing clinicians with superior specifications...ressive range of fiberoptic instruments for diagno...he demands of increasing peripheral bronchoscopy.,...
The BRO-YP2 is Fujinon's pediatric fiberoptic bronchoscope. Its small outside diameter allows for more comfortable transnasal insertion. The standard 2.0mm channel provides sufficient suction and acc
...m the latest 60 series bronchoscopes., ,Olymp... providing clinicians with superior specifications...ressive range of fiberoptic instruments for diagno...he demands of increasing peripheral bronchoscopy.,...
Medicine Products: